AngioDynamics (NASDAQ: ANGO) reported Q2 EPS of ($0.04), $0.07 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $73 million versus the consensus estimate of $70.93 million.

GUIDANCE:

AngioDynamics sees FY2025 EPS of ($0.34)-($0.38), versus the consensus of ($0.40).

The Company continues to expect net sales to be in the range of $282 to $288 million, representing growth of between 4.2% – 6.4% over fiscal 2024 pro forma revenue of $270.7 million
The Company now expects Med Tech net sales to grow in the range of 12% to 15%, an increase from 10% to 12%
The Company now expects Med Device net sales to be flat, a decrease from 1% to 3%
The Company continues to expect Gross margin to be approximately 52% to 53%
The Company now expects Adjusted EBITDA in the range of $1.0 to $3.0 million, an increase from the previous guidance of a loss of $2.5 million to $0. The updated guidance compares to a pro forma Adjusted EBITDA loss of $3.2 million in fiscal 2024.

For earnings history and earnings-related data on AngioDynamics (ANGO) click here.